Harrow Health, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Harrow Health, Inc. on February 25, 2019, reporting events occurring on February 20, 2019. The filing addresses Item 5.02 regarding the appointment of certain officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
Effective February 20, 2019, John P. Saharek was promoted to President of ImprimisRx, the Company's ophthalmology-focused pharmaceutical compounding business. Previously, Mr. Saharek served as Chief Commercial Officer since February 2015 and Vice-President of Commercialization, Ophthalmology since November 2012.
Compensation and Management Commentary
In connection with the promotion, Mr. Saharek's new compensatory arrangements include:
- Base Salary: $305,000 annually.
- Cash Incentive Bonus: Target of 50% of base salary, contingent on corporate and individual performance goals.
- Restricted Stock Units (RSUs): Up to 50,000 shares vesting on the third anniversary of the grant date, with accelerated vesting upon a change in control.
- Stock Options: Option to purchase up to 50,000 shares at fair value on the grant date, vesting in equal quarterly installments over three years.
The filing confirms no family relationships between Mr. Saharek and other directors or officers, and no related transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the vesting schedule and performance metrics for the new RSU and stock option grants.
- Review the Company's 2017 Stock Incentive Plan for details on change-in-control provisions.
- Assess the strategic impact of Mr. Saharek's promotion on the ImprimisRx ophthalmology segment.
- Confirm the absence of undisclosed related party transactions as stated in the filing.